Cadex Genomics Revenue and Competitors
Estimated Revenue & Valuation
- Cadex Genomics's estimated annual revenue is currently $1.1M per year.
- Cadex Genomics's estimated revenue per employee is $155,000
Employee Data
- Cadex Genomics has 7 Employees.
- Cadex Genomics grew their employee count by -22% last year.
Cadex Genomics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-founder & CEO | Reveal Email/Phone |
2 | Co-Founder & SVP, Medical Affairs | Reveal Email/Phone |
3 | CHIEF SCIENCE OFFICER | Reveal Email/Phone |
4 | SR. VP, MEDICAL AFFAIRS | Reveal Email/Phone |
Cadex Genomics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $79.1M | 510 | 6% | N/A | N/A |
#2 | $1.1M | 7 | 17% | N/A | N/A |
#3 | $4.2M | 27 | -32% | N/A | N/A |
#4 | $2M | 13 | 30% | N/A | N/A |
#5 | $4.3M | 28 | 4% | N/A | N/A |
#6 | $0.9M | 6 | 0% | N/A | N/A |
#7 | $5M | 32 | 3% | N/A | N/A |
#8 | $3.7M | 24 | 4% | N/A | N/A |
#9 | $0.3M | 4 | 0% | N/A | N/A |
#10 | $6M | 39 | 50% | N/A | N/A |
What Is Cadex Genomics?
Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws. Alibrex is a blood-based assay, developed to help physicians identify patients who are not responding to drug therapy. The test is optimized to maximize NPV, that is, minimize the number of false non-responders.
keywords:N/AN/A
Total Funding
7
Number of Employees
$1.1M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 7 | 40% | N/A |
#2 | $0.7M | 7 | 0% | N/A |
#3 | $0.7M | 7 | -70% | N/A |
#4 | $1.1M | 7 | 0% | N/A |
#5 | $0.5M | 7 | -22% | N/A |